Merck & Co Inc

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer

A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease

Anti-GD2 ADC M3554 in Advanced Solid Tumors

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Pembrolizumab In Central Nervous System Metastases

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia